Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Heart Failure Specialists (US)

Analysis of: Doctors See How Cancer Drug Can Damage Kidneys (www.washingtonpost.com)
This article brings more visibility to issue of effect of angiogenesis inhibitors on kidney function Other mechanisms of injury have previously been described.  Current case simply adds visibility and more definitive evidence of effect in humans Mechanism described is likely not restricted...
Brian Olshansky, MD, Professor of Medicine
Brian Olshansky, MD, Professor of Medicine
University of Iowa Hospitals and Clinics
Analysis of: Stereotaxis shares tank on Q4 loss (www.24x7mag.com)
The development of the new technology related to Stereotaxis has been slow going.  While there is much hope there is also much hype.  It is not clear that Stereotaxis really adds much to the success of catheter ablation of atrial fibrillaiton.  There has been a vocal minority...
Analysis of: PAION's anticoagulant Solulin successfully tested in first-in-man study (www.pipelinereview.com)
The field of anticoagulant compounds to be used in the prevention and  treatment of venous and arterial thrombosis is getting more crowded by the day. The new compounds are set to replace coumadin and heparin, to widely used medicines that have some serious disadvantages (heparin has also made...
Analysis of: Daiichi Sankyo, Lilly Submit Marketing Authorization Application for Investigational Oral Antiplatelet Drug; Prasugrel, to European Medicine Agency (www.pipelinereview.com)
Plasugrel is an attractive new medication for those patients undergoing cardiac catheterization with subsequent coronary intervention.  However, its niche will be with those patients at lower bleeding risk.  This is due to the fact that in the trial TRITON TIMI 38, prasugrel (which acts via...
Analysis of: FDA Approves Abbott’s Simcor Cholesterol Med (www.pharmalot.com)
Simcor does not remove the major complication that occurs with niacin which is flushing. I do not see this as a successful drug.
Analysis of: Kidney Cancer Drug Linked to Higher Rate of Heart Problems (www.washingtonpost.com)
Patients with rare malignancies, especially those with already metastatic diseases, are being treated with novel oncologic agents.  However, as is being seen with many drugs, the hemodynamic consequences of these agents, in many cases a rise in blood pressure, may lead to cardiovascular consequences. ...
Analysis of: Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172 (www.pipelinereview.com)
The oral anticoagulant market is huge and expanding. It is currently dominated by warfarin, which is widely prescribed, but which needs monthly blood draws to monitor the treatment intensity. The parenteral (non-oral) anticoagulant market is dominated by two players: [unfractioned] heparin (which is...
Analysis of: Efficacy of Botulinum Toxin Does Not Sag Over Time (www.medscape.com)
The long term efficacy of botulinum toxin Type A for the treatment of glabellar frown lines was recently discussed  in San Antonio, Texas at the 66th annual meeting of the American Association of Dermatology. Kawashima and other fellow Japanese investigators presented long-term (64 weeks)...
Analysis of: Great Drug, but Does It Prolong Life? (www.nytimes.com)
Statin therapy in lower risk populations will not have as profound an effect as in high risk subsets but still very likely has overall positive benefits.
Analysis of: Schering releases ENHANCE data today (www.tradingmarkets.com)
I anticipate vytorin and zetia sales will be down substantial when the IMS numbers come out tommorrow, but that this will be only the beginning of a negative trend for these scripts. I list below several reasons why.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next51 to 60 of 312

Analytics


Generated at 2009-01-07T13:00:17.563